97820-51-4Relevant articles and documents
Highly selective palladium-catalyzed cross-coupling of secondary alkylzinc reagents with heteroaryl halides
Yang, Yang,Niedermann, Katrin,Han, Chong,Buchwald, Stephen L.
supporting information, p. 4638 - 4641 (2015/01/08)
The highly selective palladium-catalyzed Negishi coupling of secondary alkylzinc reagents with heteroaryl halides is described. The development of a series of biarylphosphine ligands has led to the identification of an improved catalyst for the coupling of electron-deficient heterocyclic substrates. Preparation and characterization of oxidative addition complex (L)(Ar)PdBr provided insight into the unique reactivity of catalysts based on CPhos-type ligands in facilitating challenging reductive elimination processes.
Nickel-catalyzed Negishi cross-coupling reactions of secondary alkylzinc halides and aryl iodides
Joshi-Pangu, Amruta,Ganesh, Madhu,Biscoe, Mark R.
supporting information; experimental part, p. 1218 - 1221 (2011/04/27)
A general Ni-catalyzed process for the cross-coupling of secondary alkylzinc halides and aryl/heteroaryl iodides has been developed. This is the first process to overcome the isomerization and β-hydride elimination problems that are associated with the use of secondary nucleophiles, and that have limited the analogous Pd-catalyzed systems. The impact of salt additives was also investigated. It was found that the presence of LiBF4 dramatically improves both isomeric retention and yield for challenging substrates.(Figure Presented)
5-ALKYL INDOLE COMPOUNDS
-
, (2008/06/13)
Described herein are compounds selective for the 5-HT 1D-like receptor, which have the general formula: STR1 wherein: R 1 is linear or branched loweralkyl;R 2 is selected from a group of Formula II, III, IV and V: STR2 R 3 is selected from H and loweralkyl; R 4 is selected from H and loweralkyl; One of R. sup. 5 and R 6 is H and the other is independently selected from H, loweralkoxy, loweralkyl and hydroxy; andn is 1-3; or a salt, solvate or hydrate thereof.Also described is the use of these compounds as pharmaceuticals to treat indications where stimulation of the 5-HT 1D-like receptor is implicated, such as migraine.